Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Surgical Infections|December 7, 2011
Selection of prophylactic antimicrobial agent may affect incidence of infection in small bowel and colorectal surgeryKathryn J Eagye, David P Nicolau
American Journal of Surgery|March 25, 2009
Deep and organ/space infections in patients undergoing elective colorectal surgery: incidence and impact on hospital length of stay and costsKathryn J Eagye, David P Nicolau
The Journal of Antimicrobial Chemotherapy|April 5, 2011
Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenemKathryn J Eagye, David P Nicolau
Advances in Therapy|March 30, 2011
Fluoroquinolone use is not associated with the change in imipenem susceptibility of Pseudomonas aeruginosa in 25 hospitalsKathryn J Eagye, David P Nicolau
Infection Control and Hospital Epidemiology|March 26, 2010
Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitalsKathryn J Eagye, David P Nicolau
Infection Control and Hospital Epidemiology|July 9, 2009
Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosaKathryn J Eagye, Joseph L Kuti, David P Nicolau
Critical Care Medicine|March 20, 2012
Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapyKathryn J Eagye, Mary A Banevicius, David P Nicolau
Surgical Infections|April 18, 2007
Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profilingKathryn J Eagye, Joseph L Kuti, David P Nicolau
Seminars in Respiratory and Critical Care Medicine|February 10, 2009
Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumoniaKathryn J Eagye, David P Nicolau, Joseph L Kuti
Clinical Therapeutics|August 19, 2007
Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulationKathryn J Eagye, Joseph L Kuti, Michael Dowzicky, et al.
Pageof 2